MX2022002038A - Composicion farmaceutica para el tratamiento del insomnio. - Google Patents

Composicion farmaceutica para el tratamiento del insomnio.

Info

Publication number
MX2022002038A
MX2022002038A MX2022002038A MX2022002038A MX2022002038A MX 2022002038 A MX2022002038 A MX 2022002038A MX 2022002038 A MX2022002038 A MX 2022002038A MX 2022002038 A MX2022002038 A MX 2022002038A MX 2022002038 A MX2022002038 A MX 2022002038A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
lemborexant
pharmaceutically acceptable
acceptable salt
treating insomnia
Prior art date
Application number
MX2022002038A
Other languages
English (en)
Inventor
Takashi Ueno
Edgar SCHUCK
Landry Ishani Savant
Kenya Nakai
Yukiko Miyajima
Yosuke Nakatani
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2022002038A publication Critical patent/MX2022002038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención proporciona una composición farmacéutica oral para tratar el insomnio, que comprende lemborexant o una sal farmacéuticamente aceptable del mismo, en donde una dosis normal del lemborexant o de la sal farmacéuticamente aceptable del mismo es de 5 a 10 mg al día, siempre que una dosis del lemborexant o de la sal farmacéuticamente aceptable del mismo sea de 2.5 mg al día cuando la composición farmacéutica se administre a un paciente junto con el agente capaz de inhibir moderada o fuertemente el CYP3A y/o una dosis del lemborexant o de la sal farmacéuticamente aceptable del mismo sea de 5 mg al día cuando la composición farmacéutica se administre al paciente junto con el agente capaz de inhibir débilmente el CYP3A.
MX2022002038A 2019-09-13 2020-08-19 Composicion farmaceutica para el tratamiento del insomnio. MX2022002038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2019051141 2019-09-13
PCT/US2020/046894 WO2021050219A1 (en) 2019-09-13 2020-08-19 Pharmaceutical composition for treating insomnia

Publications (1)

Publication Number Publication Date
MX2022002038A true MX2022002038A (es) 2022-03-11

Family

ID=74865833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002038A MX2022002038A (es) 2019-09-13 2020-08-19 Composicion farmaceutica para el tratamiento del insomnio.

Country Status (10)

Country Link
US (1) US20220331309A1 (es)
EP (1) EP3993801A4 (es)
JP (1) JP2022547388A (es)
KR (1) KR20220061950A (es)
CN (1) CN114502167A (es)
AU (1) AU2020347078A1 (es)
BR (1) BR112022002949A2 (es)
CA (1) CA3151634A1 (es)
MX (1) MX2022002038A (es)
WO (1) WO2021050219A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG34208A1 (en) 1995-03-01 1996-12-06 Guy Andrew Vaz Blast and fragment resistant polyurethane boot sole for safety footwear
CA2220036A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6159605A (en) 1997-02-18 2000-12-12 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Ink-jet recording sheet
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
KR100327888B1 (ko) 1999-07-14 2002-03-09 정숭렬 도로포장 파손촉진 시험장치의 무선제어 시스템
MX2017004950A (es) * 2014-10-23 2018-01-16 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна
WO2019024845A1 (zh) * 2017-08-01 2019-02-07 苏州科睿思制药有限公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Also Published As

Publication number Publication date
US20220331309A1 (en) 2022-10-20
EP3993801A4 (en) 2023-07-19
WO2021050219A1 (en) 2021-03-18
KR20220061950A (ko) 2022-05-13
CA3151634A1 (en) 2021-03-18
EP3993801A1 (en) 2022-05-11
AU2020347078A1 (en) 2022-03-03
BR112022002949A2 (pt) 2022-06-07
CN114502167A (zh) 2022-05-13
JP2022547388A (ja) 2022-11-14

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2019012884A (es) Terapia de combinacion.
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MXPA05012810A (es) Formas de dosis oral de memantina.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2019001596A (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
JP2016505050A5 (es)
NZ751972A (en) Treatment of prurigo nodularis
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX2022002038A (es) Composicion farmaceutica para el tratamiento del insomnio.
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2022004739A (es) Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo.
MX2021008329A (es) Farmaco profilactico o terapeutico para enfermedades neurodegenerativas.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты